RFiD Discovery Launches Automated Contact Tracing Solution for Hospitals

Key Takeaways

• BLE wristbands record proximity data without manual entry
• Real-time alerts enable rapid outbreak containment
• System integrates with existing hospital IT infrastructure
• Scalable from entry-level to full location services
• Deployed in over 200 hospitals across Europe

Pulse Analysis

Hospitals have long wrestled with manual contact‑tracing, a labor‑intensive process that often misses fleeting interactions in busy wards. The rise of infectious threats, from seasonal flu to novel pathogens, has amplified the need for instantaneous exposure data. By automating proximity capture, RFiD Discovery’s solution eliminates human error and delivers a comprehensive interaction log, allowing infection‑prevention teams to act on precise, time‑stamped information rather than retrospective estimates.

The technology hinges on Bluetooth Low Energy, a low‑power protocol ideal for continuous monitoring in clinical environments. Patients wear lightweight wristbands while staff carry BLE‑enabled badges; a network of gateway readers and anchors maps every encounter, recording distance, duration and location. This data streams to a cloud‑based analytics platform that applies configurable risk rules, generating real‑time alerts and visual dashboards. Because the system plugs into existing hospital networks, implementation is swift, and the architecture can be extended to asset tracking, sterilization monitoring, and patient flow optimization, creating a unified location‑services ecosystem.

From a market perspective, the solution positions RFiD Discovery as a key player in the burgeoning digital‑health infrastructure space. With deployments in over 200 facilities, the company demonstrates scalability and credibility, appealing to health systems seeking to modernize infection control without overhauling legacy systems. As regulatory scrutiny on hospital‑acquired infections intensifies, automated tracing offers a tangible pathway to meet compliance, lower liability, and improve patient outcomes, likely spurring broader adoption across Europe and beyond.